IIPR heads into its Q2 earnings today with a distinctive tension: short sellers are quietly reducing positions, yet the stock is down sharply, and the options market is signaling unusual calm for a name this contested.
Short interest remains genuinely elevated at nearly 14% of the free float — a level that keeps IIPR firmly in high-conviction bear territory. Yet the direction has shifted. Shorts trimmed roughly 5% of their position over the past week and are down about 2% on the month, suggesting some covering ahead of the print. Crucially, the borrow market offers no squeeze signal. Availability is running at 257% — meaning lenders hold more than two and a half shares available for every share already borrowed — and cost to borrow is just 0.44%, cheap despite a 39% rise on the week. The ORTEX short score holds at 71.4, well into the upper range, reflecting the persistence of bearish positioning even as the absolute short count edges lower. Against this, the stock has shed about 7.5% over the past month to $58.59, underperforming peers like ILPT (-6.4% on the week) and STAG (-6.9%), but from a year-to-date base that was still up roughly 24%.
Options positioning has actually turned more bullish than usual into the print — a contrast worth noting. The put/call ratio hit 0.90, sitting about one standard deviation below its 20-day average of 1.01 and touching the lowest level of the past year. That reverses a prior pattern: through June and early July, PCR ran consistently above 1.20, indicating heavy demand for downside protection. The shift suggests options traders have reduced their hedges or are positioning for upside, even as the stock slides and the Street remains bearish.
That bearish Street stance is the clearest structural headwind. The consensus sits at sell, with only one analyst holding an underperform rating on record. Piper Sandler raised its target to $51 earlier this month — still roughly 13% below the current price of $58.59 — maintaining its Underweight view. The bull case rests on improved funding costs for the IQHQ investment and the company's anti-illicit cannabis retail initiatives. Bears point to a recurring pattern of tenant defaults, rising legal costs, and an active SEC investigation, alongside overcapacity risk across both cannabis and life science real estate. Those structural concerns have kept Piper Sandler anchored below the stock for years. One bright spot in the data: the dividend score ranks in the 98th percentile, and forward EPS momentum has improved materially, with the 12-month forward EPS trajectory strong enough to push growth factor scores toward the upper quartile.
The earnings print will test whether IIPR's improved financing picture and any progress on tenant collections can justify a stock trading well above even the most constructive analyst targets — or whether the SEC investigation and default pipeline have the last word.
See the live data behind this article on ORTEX.
Open IIPR on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
